Amorphous Solid Dispersions: A Promising Strategy to Overcome Solubility Challenges in Anticancer Drug Delivery

Cancer remains a major global health concern, with incidence rates rising significantly in both developed and developing nations. Conventional anticancer treatments, particularly oral therapy, are frequently restricted by many pharmacological compounds with inadequate absorption and low solubility in water. A large proportion of newly discovered anticancer agents fall into BCS Class II and IV, characterized by poor solubility &/or limited permeability, resulting in inadequate systemic exposure and inconsistent therapeutic response To overcome solubility-related challenges, various formulation strategies have been explored, including nanosuspensions, micelles, liposomes, cyclodextrin complexes, and amorphous systems. Among these, ASDs have emerged as being best methods for enhancing solubility and dissolution rate. The amorphous state presents higher Gibbs free energy compared to crystalline forms, promoting faster dissolution and improved bioavailability. However, due to thermodynamic instability, amorphous drugs tend to recrystallize. Incorporating suitable polymers can inhibit crystallization, stabilize the amorphous form, & prolong supersaturation during gastrointestinal dissolution.ASD technology has evolved through several generations. Early systems involved simple polymer matrices, while later generations incorporated surfactants and stabilizers to enhance solubility & prevent recrystallization. Fourth-generation ASDs, also known as controlled-release solid dispersions (CRSDs), designed to improve both solubility and release kinetics, making them particularly beneficial for anticancer drugs requiring sustained plasma levels. Several manufacturing techniques are used to produce ASDs, including hot melt extrusion, spray drying, freeze drying, ball milling, etc. Among these, hot melt extrusion & spray drying are generally used extensively due to their scalability, continuous processing potential, & suitability for temperature-sensitive APIs when optimized.Characterization of ASDs requires analytical techniques such as Differential Scanning Calorimetry X-ray Powder Diffraction, FTIR spectroscopy, Raman spectroscopy, & Scanning Electron Microscopy to confirm amorphicity, molecular interactions, & physical stability.Overall, ASDs represent a promising formulation platform to enhance solubility-limited anticancer drugs, improve therapeutic outcomes, and enable effective oral delivery.